SCHEMBL5700128

SCHEMBL5700128

C=C(C)c1ccncc1S(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.38
KDM4E B2RXH2 2/20 0.38
KDM6B O15054 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
KDM4A O75164 1/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA12 O43570 8/20 0.38
CA2 P00918 8/20 0.38
CA9 Q16790 8/20 0.38
CA1 P00915 7/20 0.38
CA14 Q9ULX7 6/20 0.38
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5700098 0.86 TDP1 (0.37) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL5617078 0.79 TDP1 (0.53) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL22322436 0.77 CYP2A6 (0.41) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL5700237 0.76 KDM4E (0.58) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL16852630 0.74 TDP1 (0.41) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL5700390 0.73 MAPT (0.39) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL5700400 0.73 TDP1 (0.42) KDM4CKDM4EKDM6BALDH1A1MAPT
SCHEMBL19144940 0.71 L3MBTL1 (0.44) ALDH1A1TDP1L3MBTL1CA12CA2
SCHEMBL8148133 0.71 CA12 (0.43) ALDH1A1TDP1L3MBTL1CA12CA2
SCHEMBL526501 0.69 CCNC (0.36) KDM4CKDM4EKDM6BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270582-B1 TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES MITSUBISHI RAYON CO (JP) 2006-08-30 EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 KDM4C 2243/4885KDM4E 2983/4885KDM6B 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.